Harbor Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Harbor Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-15,000	Closed	-$213K	–	182
2018 Q1	$213K	Hold	15,000	–	–	0.07%	156
2017 Q4	$219K	Hold	15,000	–	–	0.07%	151
2017 Q3	$190K	Hold	15,000	–	–	0.07%	150
2017 Q2	$178K	Hold	15,000	–	–	0.07%	134
2017 Q1	$222K	Buy	+15,000	New	+$243K	0.09%	117

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Harbor Advisors's HZNP Position: Q2 2018 in Review

Harbor Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2018, closing a stake of 15,000 shares — an estimated $213K sold.

Harbor Advisors first reported a position in HZNP in Q1 2017 and held it in 5 quarters. The position peaked at $222K in Q1 2017. 204 funds tracked by Wall St. Rank hold HZNP as of Q2 2018.

Harbor Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2018 after selling out during the quarter.
Harbor Advisors sold 15,000 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2018, an estimated $213K.
Harbor Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2017 and held it in 5 quarters.
Harbor Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $222K in Q1 2017.
204 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2018.

Based on Harbor Advisors's 13F filing for Q2 2018, filed 7 Aug 2018.